SecBot SecBot
8-K ·Filed Aug 17, 2026

FULC

Fulcrum Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed3mo ago SEC0001193125-26-353278
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▲ Bullish

This is a transformative reverse merger that hands control of the public entity to Slate Medicines. FULC shareholders face massive dilution as Slate's valuation dwarfs Fulcrum's, but receive a pre-closing cash dividend of excess net cash. The combined company will have a new pipeline and ~$245M in fresh capital. Monitor the shareholder vote and HSR clearance timeline. The deal effectively makes FULC a new biotech with Slate's programs.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.84
T+0 close · Aug 17, 2026 · via day close
Latest settled
−3.13%
T+60 · $3.72
Vs SPY
−0.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $3.84entry
  2. T+1 · 3mo ago +0.78%α +1.46% · $3.87
  3. T+5 · 3mo ago 0.00%α +1.19% · $3.84
  4. T+20 · 2mo ago −1.56%α +0.42% · $3.78
  5. T+60 · 7d ago −3.13%α −0.18% · $3.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fulcrum Therapeutics (FULC) entered into a definitive merger agreement to acquire Slate Medicines in a reverse-merger transaction. Fulcrum will issue shares to Slate stockholders at an exchange ratio based on a $350M company valuation (plus a concurrent $245M PIPE investment), while Fulcrum is valued at $31.3M. The combined company will operate as Slate Medicines, with Slate's management taking control. Fulcrum stockholders will receive a pre-closing cash dividend of excess net cash above $20.3M. The deal requires shareholder approval and HSR clearance, with a February 28, 2027 outside date. This is a transformative event that effectively hands control to Slate, making FULC a new entity with a new pipeline and substantial cash from the PIPE.

Key Financial Metrics

Deal Value
$350.0M
Deal Type
merger
Offering Size
$245.0M

Key Facts

  • Fulcrum Therapeutics to acquire Slate Medicines via reverse merger; Slate valued at $350M pre-money, Fulcrum at $31.3M.
  • Concurrent $245M PIPE investment from institutional investors at Slate's pre-money valuation.
  • Fulcrum stockholders to receive a pre-closing cash dividend of excess net cash above $20.3M target.
  • Combined company to be renamed Slate Medicines, with Slate's management and board taking control.
  • Fulcrum CEO Alex Sapir and CFO Alan Musso will depart; Slate CEO Gregory Oakes to lead combined entity.
  • Fulcrum's existing pipeline (losmapimod) is effectively being wound down; combined entity will focus on Slate's programs.
  • Deal requires Fulcrum stockholder approval for share issuance and reverse stock split; HSR waiting period must expire.
  • Fulcrum's VP of Finance Greg Tourangeau departed 7 days prior to deal announcement, replaced by CFO Musso.

Financial Impact

Reverse merger values Slate at $350M pre-money plus $245M PIPE = $595M total; Fulcrum valued at $31.3M. Combined entity will have Slate's pipeline and substantial cash from PIPE.

valuationcashdilutioncontrol

Risk Factors

  • Shareholder vote may fail; Fulcrum's 0% analyst bullish consensus suggests potential opposition.
  • HSR review could delay or block the transaction.
  • Integration risk: Fulcrum's losmapimod program is being wound down; combined entity's pipeline is unproven.
  • Pre-closing cash dividend reduces cash available to combined company; net cash at closing must be ≥ $0 after dividend.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-353278
Document: d136791dex104.htm0001193125-26-353278
Document: d136791dex105.htm0001193125-26-353278

Track record

23 reports on FULC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  5. Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  6. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  7. Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
  8. Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
  9. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
  10. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026